MT2013-31: Allo HCT for Metabolic Disorders and Severe Osteopetrosis

Inclusion Criteria: * 0 through 55 years of age * Adequate graft available * Adequate organ function * Eligible Diseases: * Mucopolysaccharidosis Disorders: * MPS IH (Hurler syndrome) * MPS II (Hunter syndrome) if the patient has no or minimal evidence of symptomatic neurologic disease but is expected to have a neurologic phenotype * MPS VI (Maroteaux-Lamy syndrome) * MPS VII (Sly syndrome) * Glycoprotein Metabolic Disorders: * Alpha mannosidosis * Fucosidosis * Aspartylglucosaminuria * Sphingolipidoses and Recessive Leukodystrophies: * Globoid cell leukodystrophy * Metachromatic leukodystrophy * Niemann-Pick B patients (sphingomyelin deficiency) * Niemann-Pick C subtype 2 * Peroxisomal Disorders: * Adrenoleukodystrophy with cerebral involvement * Zellweger syndrome * Neonatal Adrenoleukodystrophy * Infantile Refsum disease * Acyl-CoA-Oxidase Deficiency * D-Bifunctional enzyme deficiency * Multifunctional enzyme deficiency * Alpha-methylacyl-CoA Racmase Deficiency (AMACRD) * Mitochondrial Neurogastrointestingal Encephalopathy (MNGIE) * Severe Osteopetrosis (OP) * Hereditary Leukoencephalopathy with axonal spheroids (HDLS; CSF1R mutation) * Other Inherited Metabolic Disorders (IMD): Patients will also be considered who have other life-threatening, rare lysosomal, peroxisomal or other similar inherited disorders characterized by white matter disease or other neurologic manifestat…